Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder

Acta Clinica Croatica

Volumn 53, Issue 1, 2014, Pages 55-71

  Martinac, Marko ^a   Pehar, Davor ^a   Karlović, Dalibor ^b   Babić, Dragan ^c   Marčinko, Darko ^d   Jakovljević, Miro ^d  

^a Health Center Mostar   (Bosnia and Herzegovina)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

^d UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Cytokines; Depressive disorder; Hypothalamic hypophyseal system; Metabolic syndrome X

Indexed keywords

CYTOKINE; GLUCOCORTICOID; HYDROCORTISONE;

CORRELATION ANALYSIS; CYTOKINE RELEASE; DATA BASE; DEPRESSION; DISEASE ASSOCIATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; INFLAMMATION; MEDLINE; METABOLIC SYNDROME X; MOLECULAR BIOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; PSYCHOLOGICAL ASPECT;

DEPRESSIVE DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; METABOLIC SYNDROME X; PITUITARY-ADRENAL SYSTEM;

EID: 84904540909     PISSN: 03539466     EISSN: 13339451     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. JAKOVLJEVIĆ M, CRNČEVIĆ Ž, LJUBIČIĆ D{stroke}, BABIĆ D, TOPIĆ R, ŠARIĆ M. Mental disorders and metabolic syndrome: a fata morgana or warning reality? Psychiatr Dan-ub 2007;19:75-86.
2. LAKKA HM, LAAKSONEN DE, LAKKA TA, NIS-KANEN LK, KUMPUSALO E, TUOMILEHTO J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged man. JAMA 2002;28:2709-16.
3. MOKDAD AH, FORD ES, BOWMAN BA, DIETZ WH, VINICOR F, BALES VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2003;289:76-9.
4. TAKESHITA J, MASAKI K, AHMED I, FOLEY DJ, LI YQ, CHEN R, et al. Are depressive symptoms a risk factor for mortality in elderly Japanese American men? The Hono-lulu-Asian Aging Study. Am J Psychiatry 2002;159:1127-32.
5. PERLMUTTER JB, FRISHMAN WH, FEINSTEIN RE. Major depression as a risk factor for cardiovascular disease: therapeutic implications. Heart Dis 2000;2:75-82.
6. ANDERSON RJ, FREEDLAND KE, CLOUSE RE, LUSTMAN PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2000;24:1069-78.
7. MARTINAC M, KARLOVIĆ D, MARČINKO D, BABIĆ D, MASLOV B, JAKOVLJEVIĆ M. Mental disorders and metabolic syndrome. Socijalna Psihijatrija 2007;35:13-20.
8. FORD ES, GILES WH, DIETZ WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
9. ECKEL RH, GRUNDY SM, ZIMMET PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
10. BALKAU B, VALENSIC P, ESCHWÈGE E, SLAMAD G. A review of the metabolic syndrome. Diabete Metab 2007;33:405-13.
11. VEGA GL. Obesity, the metabolic syndrome, and cardiovascular disease. Am Heart J 2001;142:1108-16.
12. GRUNDY SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-36.
13. MONTAGUE C, O'RAHILLY S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49:883-8.
14. WAJCHENBERG BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
15. DESPRES JP. Our passive lifestyle, our toxic diet, and the atherogenic/diabetogenic metabolic syndrome: can we afford to be sedentary and unfit. Circulation 2005;112:453-5.
16. GARBER AJ. The metabolic syndrome. Med Clin North Am 2004;88:837-46.
17. MOLLER DE, KAUFMAN KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56:45-62.
18. MUNTNER P, HE J, CHEN J, FONSECA V, WHEL- TON PK. Prevalence of nontraditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004;14:686-95.
19. BANFI C, ERIKSSON P, GIANDOMENICO G, MUS- SONI L, SIRONI L, HAMSTEN A, et al. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes 2001;50:1522-30.
20. ADIELS M, BOREN J, CASLAKE MJ, STEWART P, SORO A, WESTERBACK AJ, et al. Overproduction of VLDL driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1697-703.
21. ROBERGE C, CARPENTIER AC, LANGLOIS MF, BAILLARGEON JP, ARDILOUZE JL, MAHEUX P, et al. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab 2007;293:1465-78.
22. DeFRONZO RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835.
23. RYDÉN M, ARNER P. Tumor necrosis factor-α in human adipose tissue - from signaling mechanisms to clinical impli- cations. J Intern Med 2007;262:431-8.
24. FEREIRA I, TWISK JW, van MECHELEN W, KEM- PER HC, STEHOUWER CD. Development of fatness, fitness, and lifestyle from adolescence to the age of 36 years: determinants of the metabolic syndrome in young adults: the Amsterdam Growth and Health Longitudinal Study. Arch Intern Med 2005;165:42-8.
25. KOVACS P, STUMVOLL M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 2005;19:625-35.
26. HSUEH WA, LYON CJ, QUINONES MJ. Insulin resistance and the endothelium. Am J Med 2004;117:109-17.
27. YANNAKOULIA M, YIANNAKOURIS N, BLUHER S, MATALAS AR, KLIMIS-ZACAS D, MANTZOROS CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in humans. J Clin Endocrinol Metab 2003;88:1730-6.
28. KUBASZEK A, PIHLAJAMAKI J, KOMAROVSKI V, LINDI V, LINDSTROM J, ERIKSSON J, et al. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C- 174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: The Finish Diabetes Prevention Study. Diabetes 2003;52:1872-6.
29. TASKINEN MR. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia 2003;46:733-49.
30. Executive summary of the Third Report of the National Cho- lesterol Education Program (NCEP) Expert Panel on detec- tion, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
31. GOLD PW, CHROUSOS GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Mol Psychiatry 2002;7:254-75.
32. TSIGOS C, CHROUSOS GP. Hypothalamic-pituitary- adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002;53:865-71.
33. BJORNTORP P, ROSMOND R. Hypothalamic origin of the metabolic syndrome X. Ann N Y Acad Sci 1999;892:297-307.
34. BRUNER EJ, HEMINGWAY H, WALKER BR, PAGE M, CLARKE P, JUNEJA M, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002;106:2659-65.
35. BJORNTORP P. Visceral obesity: a "civilization syndrome". Obes Res 1993;1:206-22.
36. STARKMAN MN, GEBARSKI SS, BERENT S, SCHTEINGART DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. Biol Psychiatry 1992;32:756-65.
37. GOLDBACHER EM, MATTHEWS KA. Are psychological characteristics related to risk of the metabolic syndrome? A review of the literature. Ann Behav Med 2007;34:240-52.
38. BRANDACHER G, HOELLER E, FUCHS D, WEISS HG. Chronic immune activation underlies morbid obesity: Is IDO a key player? Curr Drug Metab 2007;8:289-95.
39. WEISS R, DZIURA J, BURGERT TS, TAMBORLANE WV, TAKSALI SE, YECKEL CW, ALLEN K, LOPES M, SAVOYE RS, CAPRIO S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-74.
40. ZAMBON A, PAULETTO P, CREPALDI G. The metabolic syndrome - a chronic cardiovascular inflammatory con- dition. Aliment Pharmacol Ther 2005;22(Suppl 2):20-23.
41. FESTA A, D'AGOSTINO R Jr, HOWARD G, MYK- KANEN L, TRACY RP, HAFFNER SM. Chronic sub-clinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
42. HAN TS, SATTAR N, WILLIAMS K, GONZALES- WILLAPANDO C, LEAN ME, HAFFNER SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-21.
43. LEE YH, PRATLEY RE. The evolving role of inflammation and obesity and the metabolic syndrome. Curr Diab Rep 2005;5:70-5.
44. WEISBERG SP, McCAN D, DESAI M, ROSENBAUM M, LEIBEL RL, FERRANTE AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin In- vest 2003;112:1796-808.
45. SANTOS AC, LOPES C, GUIMARAES JT, BARROS H. Central obesity as a major determinant of increased high- sensitivity C-reactive protein in metabolic syndrome. Int J Obes 2005;29:1452-6.
46. WELLEN KE, HOTAMISLIGIL GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-8.
47. GRUNDY SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002;105:2696-8.
48. MERTENS I, Van der PLANKEN M, CORTHOUTS B, WAUTERS M, PEIFFER F, De LEEUW I, et al. Visceral fat is determinant of PAI-1 activity in diabetic and non- diabetic overweight and obese women. Horm Metab Res 2001;33:602-7.
49. XU H, BARNES GT, YANG Q, TAN G, YANG D, CHOU CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity related insulin resistance. J Clin Invest 2003;112:1821-30.
50. ARNER P. Insulin resistance in type 2 diabetes - role of adipokines. Curr Mol Med 2005;5:333-9.
51. RIDKER PM, WILSON PW, GRUNDY SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
52. RIDKER PM, HENNEKENS CH, BURING JE, RIFAI N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
53. GLUND S, KROOK A. Role of interleukin-6 signaling in glucose and lipid metabolism. Acta Physiol 2008;192:37-48.
54. STEENSBERG A, DALSGAARD MK, SECHER NH, PEDERSEN BK. Cerebrospinal fluid IL-6, HSP72, and TNF-α in exercising humans. Brain Behav Immun 2006;20:585-9.
55. STENLOF K, WERNSTEDT I, FJALLMAN T, WAL- LENIUS V, WALLENIUS K, JANSSON JO. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab 2003;88:4379-83.
56. th edn. Baltimore, Philadelphia: Lippincott Wil- liams and Wilkins, 2003.
57. BARDEN N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J Psychiatry Neurosci 2004;29:185-93.
58. KHAIROVA RA, MACHADO-VIEIRA R, DU J, MAN- JI HK. A potential role for proinflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009;12:561-78.
59. SAPOLSKY RM. Glucocorticoid toxicity in the hippocampus: temporal aspects of neuronal vulnerability. Brain Res 1985;359:300-5.
60. SAPOLSKY RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35.
61. McEWEN BS, MAGARINOS AM. Stress and hippocam- pal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharmacol 2001;16:7-19.
62. McEWEN BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci 2001;933:265-77.
63. REUL JMHM, de KLOET ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505-12.
64. YOUNG EA, HASKETT RF, MURPHY-WEINBERG V, WATSON SJ, AKIL H. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry 1991;48:693-9.
65. BROWN ES, VARGHESE FP, McEWEN BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry 2004;55:1-9.
66. SCHIEPERS OJ, WICHERS MC, MAES M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201-17.
67. ELENKOV IJ. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int 2008;52:40-51.
68. ADLER UC, MARQUES AH, CALIL HM. Inflammatory aspects of depression. Inflamm Allergy Drug Targets 2008;7:19-23.
69. DU J, CRESON TK, WU LJ, REN M, GRAY NA, FALKE C, et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci 2008;28:68-79.
70. DU J, SUZUKI K, WEI Y, WANG Y, BLUMENTHAL R, CHEN Z, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor mem- brane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007;32:793-802.
71. SMITH RS. The macrophage theory of depression. Med Hypotheses 1991;35:298-306.
72. YIRMIYA R, editors. Cytokines, stress and depression. New York: Kluwer Academic/Plenum Publishers, 1999;25-46.
73. YIRMIYA R, POLLAK Y, MORAG M, REICHEN-BERG A, BARAK O, AVITSUR R, et al. Illness, cytokines, and depression. Ann N Y Acad Sci 2000;917:478-87.
74. HAYLEY S, POULTER MO, MERALI Z, ANISMAN H. The pathogenesis of clinical depression: stressor and cytokine-induced alterations of neuroplasticity. Neuroscience 2005;135:659-78.
75. O'BRIEN SM, SCOTT LV, DINAN TG. Cytokine ab- normalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol Clin Exp 2004;19:397-403.
76. KIM YK, NA KS, SHIN KH, JUNG HY, CHOI SH, KIM JB. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1044-53.
77. KARLOVIĆ D, SERRETTI A, VRKIĆ N, MARTINAC M, MARČINKO D. Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melan- cholic or atypical features. Psychiatry Res 2012;198:74-80.
78. CRNKOVIĆ D, BULJAN D, KARLOVIĆ D, KRMEK A. Connection between inflammatory markers, antidepressants and depression. Acta Clin Croat 2012;51:25-33.
79. DANTZER R, O'CONNOR JC, FREUND GG, JOHN- SON RW, KELLEY KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
80. DANTZER R, CAPURON L, IRWIN MR, MILLER AH, OLLAT H, PERRY VH, ROUSEY S, YIRMIYA R. Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 2008;33:18-29.
81. MAES M. Cytokines in major depression. Biol Psychiatry 1994;36:498-9.
82. McNALLY L, BHAGWAGAR Z, HANNESTAD J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectrums 2008;13:501-10.
83. MILLER AH, RAISON CL. Cytokines, p38 MAP kinase and the pathophysiology of depression. Neuropsychopharmacology 2006;31:2089-90.
84. RAISON CL, CAPURON L, MILLER AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
85. FRASURE-SMITH N, LESPÉRANCE F, GRAVEL G, MASSON A, JUNEAU M, BOURASSA MG. Long-term survival differences among low-anxious, high-anxious and depressive copers enrolled in the Montreal Heart Attack Re- adjustment Trial. Psychosom Med 2002;64:571-9.
86. CAPURON L, BLUTHE RM, DANTZER R. Cytokines in clinical psychiatry. Am J Psychiatry 2001;158:1163-4.
87. CAPURON L, GUMNICK JF, MUSSELMAN DL, LAW- SON DH, REEMSNYDER A, NEMEROFF CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643-52.
88. CAPURON L, MILLER AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004;56:819-24.
89. MUSSELMAN DL, LAWSON DH, GUMNICK JF, MANATUNGA AK, PENNA S, GOODKIN RS, et al. Paroxetine for the prevention of depression induced by highdose interferon alfa. N Engl J Med 2001;344:961-6.
90. VILJOEN M, PANZER A. Proinflammatory cytokines: a common denominator in depression and somatic symptoms? Can J Psychiatry 2005;50:128.
91. th edn. Washington, DC: American Psychiatric Association Press, 1994.
92. Van CAUTER E, SPIEGEL K. Sleep as a mediator of the relationship between socioeconomic status and health: a hypothesis. Ann N Y Acad Sci 1999;896:254-61.
93. BROWN ES, RUSH AJ, McEWEN BS. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology 1999;21:474-84.
94. CIZZA G, RAVN P, CHROUSOS GP, GOLD PW. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab 2001;12:198-203.
95. VITALIANO PP, SCANLAN JM, ZHANG J, SAVAGE MV, HIRSCH IB, SIEGLER IC. A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosom Med 2002;64:418-35.
96. DEUSCHLE M, WEBER B, COLLA M, DEPNER M, HEUSER I. Effects of major depression, aging and gender upon calculated diurnal free plasma cortisol concentrations: a reevaluation study. Stress 1998;2:281-7.
97. HOLSBOER F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001;62:77-91.
98. ROSMOND R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 2005;30:1-10.
99. EVERSON-ROSE SA, MEYER PM, POWELL LH, PANDEY D, TORRÉNS JI, KRAVITZ HM, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 2004;27:2856-62.
100. ANISMAN H, MERALI Z. Cytokines, stress, and depressive illness. Brain Behav Immun 2002;16:513-24.
101. SPERNER-UNTERWEGER B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs 2005;65:1493-520.
102. LESPÉRANCE F, FRASURE-SMITH N, THÉROUX P, IRWIN M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleu- kin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry 2004;161:271-7.
103. PANAGIOTAKOS DB, PITSAVOS C, CHRYSOHOOU C, TSETSEKOU E, PAPAGEORGIOU C, CHRIST- ODOULOU G, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people the ATTICA study. Eur Heart J 2004;25:492-9.
104. FORD ES, AJANI UA, MOKDAD AH. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005;28:878-81.
105. MAES M, BOSMANS E, De JONGH R, KENIS G, VANDOOLAEGHE E, NEELS H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853-8.
106. FERNANDEZ S, KNOPF MA, BJORK SK, McGIL-LIS JP. Bone marrow-derived macrophages express functional CGRP receptors and respond to CGRP by increasing transcription of c-fos and IL-6 mRNA. Cell Immunol 2001;209:140-8.
107. LANQUILLON S, KRIEG JC, BENING-ABU-SHACH U, VEDDER H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000;22:370-9.
108. KERN PA, SAGHIZADEH M, ONG JM, BOSCH RJ, DEEM R, SIMSOLO RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-9.
109. RÄIKKÖNEN K, MATTHEWS KA, KULLER LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002;51:1573-7.
110. ROBERTS RE, DELEGER S, STRAWBRIDGE WJ, et al. Prospective association between obesity and depression: evidence from the Alameda County Study. Int J Obes Relat Metab Disord 2003;27:514-21.
111. ADAMIS D, BALL C. Physical morbidity in elderly psychiatric inpatients: prevalence and possible relations between the major mental disorders and physical illness. Int J Geriatr Psychiatry 2000;15:248-53.
112. JONAS BS, FRANKS P, INGRAM DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Fam Med 1997;6:43-9.
113. EATON WW, ARMENIAN H, GALLO J, PRATT L, FORD DE. Depression and risk for onset of type II diabetes - a prospective population-based study. Diabetes Care 1996;19:1097-102.
114. EATON WW. Epidemiologic evidence on the comorbidity of depression and diabetes. J Psychosom Res 2002;53:903-6.
115. KAWAKAMI N, TAKATSUKA N, SHIMIZU H, et al. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 1999;22:1071-6.
116. GAVARD JA, LUSTMAN PJ, CLOUSE RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 1993;16:1167-78.
117. KOVACS M, OBROSKY DS, GOLDSTON D, DRASH A. Major depressive disorder in youths with IDDM: a con- trolled prospective study of course and outcome. Diabetes Care 1997;20:45-51.
118. PENNINX BW, BEEKMAN AT, HONIG A, DEEG DJ, SCHOEVERS RA, van EIJK JT, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001;58:221-7.
119. BROWN LC, MAJUMDAR SR, NEWMAN SC, JOHN- SON JA. History of depression increases risk of type 2 diabe- tes in younger adults. Diabetes Care 2005;28:1063-7.
120. WHOOLEY MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA 2006;295:2874-81.
121. RÄIKKÖNEN K, KELTIKANGAS-JÄRVINEN L, ADLERCREUTZ H, HAUTANEN A. Psychosocial stress and the insulin resistance syndrome. Metabolism 1996;45:1533-8.
122. RÄIKKÖNEN K, MATTHEWS KA, KULLER LH. Trajectory of psychological risk and incident hypertension in middle-aged women. Hypertension 2001;38:798-802.
123. WEBER-HAMANN B, WERNER M, HENTSCHEL F, BINDEBALLE N, LEDERBOGEN F, DEUSCHLE M, et al. Metabolic changes in elderly patients with major depression: Evidence for increased accumulation of visceral fat at follow-up. Psychoneuroendocrinology 2006;31:347-54.
124. TIMONEN M, LAAKSO M, JOKELAINEN J, RA-JALA U, MEYER-ROCHOW VB, KEINANEN-KIU- KAANNIEMI S. Insulin resistance and depression: Cross sectional study. BMJ 2005;330:17-8.
125. ADRIAANSE MC, DEKKER JM, NIJPELS G, HEINE RJ, SNOEK FJ, POUWER F. Associations between depressive symptoms and insulin resistance: the Hoorn Study. Diabetologia 2006;49:2874-7.
126. McCAFFERY JM, NIAURA R, TODARO JF, SWAN GE, CARMELLI D. Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blood Institute Twin Study. Psychosom Med 2003;65:490-7.
127. HERVA A, RASANEN P, MIETTUNEN J, TIMONEN M, LAKSY K, VEIJOLA J, et al. Co-occurrence of meta- bolic syndrome with depression and anxiety in young adults: the Northern Finland 1966 Birth Cohort Study. Psychosom Med 2006;68:213-6.
128. KINDER LS, CARNETHON MR, PALANIAPPAN LP, KING AC, FORTMANN SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004;66:316-22.
129. RAIKKONEN K, MATTHEWS KA, KULLER LH. Depressive symptoms and stressful life events predict meta- bolic syndrome among middle-aged women. Diabetes Care 2007;30:872-7.
130. EMPANA JP, SYKES DH, LUC G, JUHAN-VAGUE I, ARVEILER D, FERRIERES J, et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2005;111:2299-305
131. HEISKANEN TH, NISKANEN LK, HINTIKKA JJ, KOIVUMAA-HONKANEN HT, HONKALAMPI KM, HAATAINEN KM, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006;67:1422-7
132. SAARI KM, LINDEMAN SM, VIILO KM, ISOHAN- NI MK, JÄRVELIN MR, LAURÉN LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005;66:559-63
133. KOPONEN H, JOKELAINEN J, KEINÄNEN-KIU-KAANNIEMI S, KUMPUSALO E, VANHALA M. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry 2008;69:178-82.
134. SKILTON MR, MOULIN P, TERRA JL, BONNET F. Associations between anxiety, depression, and the meta- bolic syndrome. Biol Psychiatry 2007;62:1251-7
135. TAKEUCHI T, NAKAO M, NOMURA K, YANO E. Association of metabolic syndrome with depression and anxiety in Japanese men. Diabetes Metab 2009;35:32-6.
136. CAPURON L, SU S, MILLER AH, BREMNER JD, GOLDBERG J, VOGT GJ, et al. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry 2008;64:896-900
137. World Health Organization. World Health Report 2001, Mental Health: New Understanding, New Hope. Geneva: WHO, 2001. 70 Acta Clin Croat, Vol. 53, No. 1, 20